BCL2 and acute myeloid leukemia: However, for the last 2 or 3 years, a plethora of agents which target some specific mutations or cell survival signal pathways have been approved by FDA for AML treatment including FLT3 inhibitor, IDH2/IDH1 inhibitor, and BCL-2 inhibitor [20, 56].